Position in ERAS
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$6,580,438
New position
Shares Held
406,702
first reported quarter
Ownership
0.131%
of shares outstanding
% of Portfolio
0.68%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Parkman Healthcare Partners LLC holds $362,342,788 across 36 Biotechnology names. ERAS ranks #19 (1.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | KALV |
KalVista Pharmaceuticals, Inc.
|
1,835,506 | $36,948,735 | |
| 2 | PTCT |
Ptc Therapeutics, Inc.
|
431,364 | $29,388,829 | |
| 3 | XENE |
Xenon Pharmaceuticals Inc.
|
497,035 | $28,902,585 | |
| 4 | RCUS |
Arcus Biosciences, Inc.
|
1,207,274 | $26,077,118 | |
| 5 | MBX |
MBX Biosciences, Inc.
|
800,037 | $23,881,104 | |
| 6 | SNDX |
Syndax Pharmaceuticals Inc
|
901,511 | $21,059,296 | |
| 7 | EYPT |
EyePoint, Inc.
|
1,354,800 | $17,463,372 | |
| 8 | AGIO |
Agios Pharmaceuticals, Inc.
|
403,525 | $13,651,250 |
All Filings in ERAS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $6,580,438 | 406,702 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||